![](https://endpts.com/wp-content/uploads/2023/08/Peter-Maag.jpg)
Peter Maag, Kyverna Therapeutics CEO
Kyverna Therapeutics adds $60M to the bank as it prepares to showcase early CAR-T data in lupus nephritis
Kyverna Therapeutics’ anti-CD19 CAR-T is drawing new investors to lead a $60 million infusion, reloading as it steers through early clinical trials in autoimmune diseases …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.